Investigating how a specific protein modification affects gut inflammation
PARP1 and PARylation as novel effectors of gut inflammation
This study is looking at how a process called PARylation affects gut inflammation in people with conditions like Inflammatory Bowel Diseases (IBD), and it hopes to find ways to improve healing by understanding how gut bacteria and the immune system work together.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11083677 on NIH RePORTER |
What this research studies
This research explores the role of poly-ADP-ribosylation (PARylation) in gut inflammation, particularly in conditions like Inflammatory Bowel Diseases (IBD). It examines how this modification influences the interaction between gut bacteria and the immune response in the colon. By studying the effects of a protein called PARP1, the research aims to understand how changes in gut microbiota can lead to inflammation and how targeting this process might help in recovery from gut injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Inflammatory Bowel Diseases, such as Crohn's disease or ulcerative colitis.
Not a fit: Patients without any gastrointestinal disorders or those who do not have a history of inflammatory bowel diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients suffering from inflammatory bowel diseases by targeting the mechanisms of gut inflammation.
How similar studies have performed: Previous research has shown promising results in understanding the role of microbiota in gut inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Kiela, Pawel R — University of Arizona
- Study coordinator: Kiela, Pawel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.